MA62924A1 - Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1 - Google Patents
Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1Info
- Publication number
- MA62924A1 MA62924A1 MA62924A MA62924A MA62924A1 MA 62924 A1 MA62924 A1 MA 62924A1 MA 62924 A MA62924 A MA 62924A MA 62924 A MA62924 A MA 62924A MA 62924 A1 MA62924 A1 MA 62924A1
- Authority
- MA
- Morocco
- Prior art keywords
- combination
- prolgolimab
- carboplatin
- cisplatin
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 230000003211 malignant effect Effects 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 229960004562 carboplatin Drugs 0.000 abstract 4
- 190000008236 carboplatin Chemical compound 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract 4
- 229960001592 paclitaxel Drugs 0.000 abstract 4
- 229940121482 prolgolimab Drugs 0.000 abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 4
- 229960000397 bevacizumab Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021109765A RU2787457C2 (ru) | 2021-04-08 | Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента | |
| PCT/RU2022/050122 WO2022216184A1 (en) | 2021-04-08 | 2022-04-08 | Malignant neoplasis treatment using pd-1 antibody combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA62924A1 true MA62924A1 (fr) | 2024-03-29 |
Family
ID=83546621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA62924A MA62924A1 (fr) | 2021-04-08 | 2022-04-08 | Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319736A1 (pt) |
| CN (1) | CN117500493A (pt) |
| AR (1) | AR125322A1 (pt) |
| BR (1) | BR112023020856A2 (pt) |
| CL (1) | CL2023003012A1 (pt) |
| CO (1) | CO2023013510A2 (pt) |
| EC (1) | ECSP23076237A (pt) |
| MA (1) | MA62924A1 (pt) |
| MX (1) | MX2023011952A (pt) |
| TW (1) | TW202304511A (pt) |
| UY (1) | UY39724A (pt) |
| WO (1) | WO2022216184A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| TW202108616A (zh) * | 2019-05-03 | 2021-03-01 | 美商建南德克公司 | 用抗pd-l1抗體治療癌症之方法 |
-
2022
- 2022-04-08 CN CN202280027483.7A patent/CN117500493A/zh active Pending
- 2022-04-08 MA MA62924A patent/MA62924A1/fr unknown
- 2022-04-08 UY UY0001039724A patent/UY39724A/es unknown
- 2022-04-08 MX MX2023011952A patent/MX2023011952A/es unknown
- 2022-04-08 TW TW111113464A patent/TW202304511A/zh unknown
- 2022-04-08 WO PCT/RU2022/050122 patent/WO2022216184A1/en active Application Filing
- 2022-04-08 BR BR112023020856A patent/BR112023020856A2/pt unknown
- 2022-04-08 AR ARP220100896A patent/AR125322A1/es unknown
- 2022-04-08 EP EP22785065.8A patent/EP4319736A1/en active Pending
-
2023
- 2023-10-06 CL CL2023003012A patent/CL2023003012A1/es unknown
- 2023-10-06 EC ECSENADI202376237A patent/ECSP23076237A/es unknown
- 2023-10-12 CO CONC2023/0013510A patent/CO2023013510A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011952A (es) | 2023-11-09 |
| BR112023020856A2 (pt) | 2024-02-06 |
| ECSP23076237A (es) | 2024-01-31 |
| EP4319736A1 (en) | 2024-02-14 |
| TW202304511A (zh) | 2023-02-01 |
| AR125322A1 (es) | 2023-07-05 |
| UY39724A (es) | 2022-10-31 |
| CN117500493A (zh) | 2024-02-02 |
| CO2023013510A2 (es) | 2023-11-10 |
| CL2023003012A1 (es) | 2024-04-12 |
| WO2022216184A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
| Vu et al. | Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients | |
| CL2022002555A1 (es) | Anticuerpos anti-ccr8 para el tratamiento del cáncer | |
| Kaiser et al. | Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MA29374B1 (fr) | Anticorps anti-ccr5 et leurs utilisations | |
| MA53069B1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
| Ferrone et al. | Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration | |
| MA44234B1 (fr) | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 | |
| MA62924A1 (fr) | Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1 | |
| TN2018000332A1 (fr) | Composition, notamment composition pharmaceutique préventive et curative, à base de peroxométallate | |
| WO2021259927A3 (en) | Anti-cd2 antibodies | |
| MA54975B1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| MA45890B2 (fr) | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes | |
| MX2021012061A (es) | Anticuerpo biespecifico. | |
| FR3103106B1 (fr) | Extrait liquide aqueux de Spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes. | |
| MX2023010764A (es) | Anticuerpo anti componente del complemento 1s (c1s). | |
| FR3062796B1 (fr) | Utilisation d'un compose appartenant a la famillle des diuretiques pour traiter le cancer | |
| MX2023001481A (es) | Metodos para tratar pacientes con hipercolesterolemia refractaria. | |
| MA56998B1 (fr) | Traitement de symptômes induits par le cycle menstruel | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MA56263A1 (fr) | Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation | |
| MA47234B1 (fr) | Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation |